SIONNA THERAPEUTICS INC (SION)
Health Care · NASDAQ
A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
What SIONNA THERAPEUTICS INC does
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule medicines to treat cystic fibrosis by stabilizing the CFTR protein's nucleotide binding domain 1 (NBD1). The company is advancing a pipeline of NBD1 stabilizers designed to work alone or in combination with complementary CFTR modulators to restore CFTR function, particularly for patients carrying the F508del mutation, which affects approximately 90% of CF patients. Lead programs include SION-719 being evaluated as an add-on to standard-of-care CF therapy and SION-451 being tested in dual combinations.
Themes: []
Fundamentals
- Price$44.94 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+104.0% as of 2026-07-09 close
- ROE-27.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.52 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.